




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07C 229/64, 323/63, 255/59, A61K 31/195, C07C 205/59	A1	(11) International Publication Number: WO 94/19315 (43) International Publication Date: 1 September 1994 (01.09.94)
(21) International Application Number: PCT/SE94/00152 (22) International Filing Date: 22 February 1994 (22.02.94) (30) Priority Data: 9300657-5 26 February 1993 (26.02.93) SE (71) Applicants (for all designated States except US): AKTIEBO- LAGET ASTRA [SE/SE]; S-151 85 Södertälje (SE). THE UNIVERSITY OF MARYLAND [US/US]; 511 West Lom- bard Street, Baltimore, MD 21202-1691 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BJÖRK, Susanna, Karin, Maria [SE/SE]; Bollvägen 69, S-151 59 Södertälje (SE). GOTTHAMMAR, Kristina, Birgitta [SE/SE]; Björkholmsvägen 188, S-132 31 Saltsjö-Boo (SE). LIN- DERBERG, Mats, Torbjörn [SE/SE]; Kämpevägen 29, S-151 54 Södertälje (SE). LUTHMAN, Per, Johan [SE/SE]; Mälargatan 1, S-646 00 Gnesta (SE). PERSSON, Kerstin, Margareta, Irma [SE/SE]; Lillhagavägen 6, S-155 31 Nykvam (SE). SCHWARCZ, Robert [AT/US]; 6936 Ten Timbers Lane, Baltimore, MD 21209 (US). (74) Agent: FREDRIKSSON, Gunilla; AB Astra, Patent Dept., S- 151 85 Södertälje (SE).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, TJ, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: NEW COMPOUNDS <div style="text-align: center;">  <p>(I)</p> </div>		
(57) Abstract <p>The present invention relates to novel derivatives of 3-hydroxyanthranilic acid, 3-HANA, of general formula (I), wherein R¹ and R² are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R³, R⁴ are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and Z-R⁵ wherein Z is selected from CH_n, NH_m, O, S, SO₂ and CO wherein n=1 or 2; m=0 or 1 and R⁵ is selected from alkyl, aryl and fluoroalkyl; or R³ and R⁴ together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C₁-C₃ alkylene or alkenylene, -N=, -N=N- and (a), wherein R₇=H or alkyl; or a pharmaceutically acceptable salt thereof, methods and intermediates for their preparation, novel pharmaceutical compositions and the use thereof for inhibiting the enzyme 3-hydroxy-anthranilate oxygenase, 3-HAO, responsible for the production of the endogenous neurotoxin quinolinic acid, QUIN.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

New Compounds

5 Field of invention

The present invention relates to novel derivatives of 3-hydroxyanthranilic acid, 3-HANA, methods and intermediates for their preparation, novel
10 pharmaceutical compositions and the use thereof for inhibiting the enzyme 3-hydroxy-anthranilate oxygenase, 3-HAO, responsible for the production of the endogenous neurotoxin quinolinic acid, QUIN.

15 Background of the invention

3-HAO is the enzyme in the catabolic pathway of tryptophan responsible for the conversion of 3-hydroxyanthranilic acid into quinolinic acid. Both QUIN
20 and its biosynthetic enzyme 3-HAO have been identified in rodent as well as in human brain tissue. QUIN is an excitatory amino acid acting through the N-methyl-D-aspartate (NMDA) receptor and has recently gained attention for its putative role as an endogenous
25 excitotoxin involved in neurodegenerative disorders such as Huntington's disease, stroke/cerebral ischemia, hypoxia, Alzheimer's disease and the Aids dementia complex as well as epilepsi. Inhibitors of 3-HAO activity are of obvious therapeutic interest in
30 diseases which can be traced to an overabundance of quinolinic acid.

Prior art

35 4-Halogenated substrate analogs have been described as inhibitors of 3-HAO activity. In 1980 it was shown by Parli CJ, Krieter P, Schmedt B, in "Metabolism of 6-

chlorotryptophan to 4-chloroanthranilic acid : A potent inhibitor of 3-hydroxyanthranilic acid oxidase", Arch Biochem and Biophys 203, pp 161-166, 1980, that 4-chloro-3-hydroxyanthranilic acid, a metabolite of 6-chlorotryptophan, is a potent inhibitor of 3-HAO in rat and pig liver and kidney. Later it was verified by Heyes MP, Hutto B, Markey SP, in " 4-Chloro-3-hydroxyanthranilate inhibits brain 3-hydroxyanthranilate oxidase" , Neurochem Int 13, pp 405-408, 1988, that 4-chloro-3-hydroxyanthranilic acid also is an inhibitor of rat brain 3-HAO. In 1989 Todd WP, Carpenter BK and Schwarcz R, in "Preparation of 4-halo-3-hydroxyanthranilates and demonstration of their inhibition of 3-hydroxyanthranilate oxygenase activity in rat and human brain tissue, " Prep Biochem 19, pp 155-165, 1989, showed that 4-fluoro-, 4-chloro- and 4-bromo-3-hydroxyanthranilic acid had very similar blocking potencies of 3-HAO in rat as well as in human brain.


20

Brief description of invention

The present invention relates to compounds able to inhibit the enzyme 3-HAO with IC₅₀ values similar to and in addition a stability superior to compounds according to the prior art.

The present invention, thus is related to a compound of the general formula I

35



wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, -N=, -N=N- and -N-R₇ wherein $R_7 = H$ or alkyl; or a pharmaceutically acceptable salt thereof.

15


Another object of the invention is a process for the preparation of the compound of formula I by

A) in the case where R^1 and $R^2 = H$; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, -N=, -N=N- and -N-R₇ wherein $R_7 = H$ or alkyl

30

reducing a compound of formula II

35




II

wherein X, R³ and R⁴ are as defined in A) above,

B) in the case where R¹ and R² are the same or
 5 different and selected from H and alkyl; X is selected
 from alkylthio, arylthio, aryloxy, halogen and cyano;
 R³, R⁴ are the same or different and selected from
 halogen, methyl, fluoroalkyl, cyano and Z-R⁵ wherein Z
 is selected from CH_n, NH_m, O, S, SO₂ and CO wherein n =
 10 1 or 2; m = 0 or 1 and R⁵ is selected from alkyl, aryl
 and fluoroalkyl; or R³ and R⁴ together form a saturated
 or unsaturated ring system Y-V-Z wherein Y and Z,
 independently of each other, are as defined for Z above
 and V is selected from C₁-C₃ alkylene or alkenylene,
 15 -N=, -N=N- and -N-R₇ wherein R₇ = H or alkyl

deprotecting a compound of formula III

20



25

wherein R¹, R², X, R³ and R⁴ are as defined in B)
 above and PG is a protecting group such as alkyl,
 benzyl (Bn), 2-(trimethylsilyl)ethoxymethyl (SEM),
 methoxymethyl (MOM) or 2-methoxyethoxymethyl (MEM),

30


C) in the case where R¹ and R² are the same or
 different and selected from H and alkyl; X is selected
 from alkylthio, arylthio, aryloxy, halogen and cyano;
 R³, R⁴ are the same or different and selected from
 halogen, methyl, fluoroalkyl, cyano and Z-R⁵ wherein Z
 is selected from CH_n, NH_m, O, S, SO₂ and CO wherein n =
 35 1 or 2; m = 0 or 1 and R⁵ is selected from alkyl, aryl
 and fluoroalkyl; or R³ and R⁴ together form a saturated

or unsaturated ring system Y-V-Z wherein Y and Z,
independently of each other, are as defined for Z above
and V is selected from C₁-C₃ alkylene or alkenylene,
-N=, -N=N- and -N-R₇ wherein R₇ = H or alkyl

5

deesterifying a compound of formula IV

10



IV


wherein R¹, R², X, R³ and R⁴ are as defined in C)
above and R⁶ is selected from alkyl, Bn, SEM, MEM, MOM
and 2,2,2-trichloroethyl,

D) in the case where R¹ and R² are the same or
different and selected from H and alkyl; X is selected
from alkylthio, arylthio, aryloxy, halogen and cyano;
R³, R⁴ are the same or different and selected from
halogen, methyl, fluoroalkyl, cyano and Z-R⁵ wherein Z
is selected from CH_n, NH_m, O, S, SO₂ and CO wherein n =
1 or 2; m = 0 or 1 and R⁵ is selected from alkyl, aryl
and fluoroalkyl; or R³ and R⁴ together form a saturated
or unsaturated ring system Y-V-Z wherein Y and Z,
independently of each other, are as defined for Z above
and V is selected from C₁-C₃ alkylene or alkenylene,
-N=, -N=N- and -N-R₇ wherein R₇ = H or alkyl

30

deesterifying and deprotecting a compound of
formula V

35




V

wherein R^1 , R^2 , X, R^3 and R^4 are as defined in D) above and R^6 and PG are selected from alkyl, Bn, SEM,
 5 MEM and MOM,

E) in the case where R^1 = alkyl, R^2 = H or alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected
 10 from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y
 15 and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl

20 alkylating a compound of formula VI




VI

25

wherein X, R^3 and R^4 are as defined in E) above.

30 F) in the case where R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, halogen and cyano; R^3 = chloro, bromo or iodo; R^4 = alkoxy, alkyl, alkylthio, cyano, fluoroalkyl, halogen, RSO_2 or RCO wherein $R = C_1-C_5$
 35 alkyl

halogenating a compound of formula VII




VII

wherein R^1 , R^2 , X and R^4 are as defined in F) above.

G) in the case where R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, halogen and cyano; R^3 = alkoxy, alkyl, alkylthio, cyano, fluoroalkyl, halogen, RSO_2 or RCO wherein $R = C_1-C_5$ alkyl and R^4 = chloro, bromo or iodo

halogenation a compound of formula VIII




VIII

wherein R^1 , R^2 , X and R^3 are as defined in G) above,
or

H) in the case where R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from chloro, bromo and iodo; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each

other, are as defined for Z above and V is selected from C₁-C₃ alkylene or alkenylene, -N=, -N=N- and -N-R₇ wherein R₇ = H or alkyl

5 halogenating a compound of formula IX



wherein R¹, R², R³ and R⁴ are as defined in H) above.


15

The present invention is also related to a pharmaceutical formulation containing a compound of formula I as active ingredient and a pharmaceutically acceptable carrier, the use of said compound for the manufacture of a medicament for the prevention or treatment of neurodegeneration.

Further objects of the invention are synthesis intermediates for the preparation of the compound of formula I, namely a compound of the general formula II

25

30




wherein X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R³, R⁴ are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and Z-R⁵ wherein Z is selected from CH_n, NH_m, O, S, SO₂ and CO wherein n = 1 or 2; m = 0 or

35

1 and R⁵ is selected from alkyl, aryl and fluoroalkyl;
 or R³ and R⁴ together form a saturated or unsaturated
 ring system Y-V-Z wherein Y and Z, independently of
 each other, are as defined for Z above and V is
 5 selected from C₁-C₃ alkylene or alkenylene, -N=, -N=N-
 and -N-R₇ wherein R₇ = H or alkyl;

a compound of the general formula III

10




15

wherein R¹ and R² are the same or different and
 selected from H and alkyl; X is selected from
 alkylthio, arylthio, aryloxy, halogen and cyano; R³, R⁴
 are the same or different and selected from halogen,
 20 methyl, fluoroalkyl, cyano and Z-R⁵ wherein Z is
 selected from CH_n, NH_m, O, S, SO₂ and CO wherein n = 1
 or 2; m = 0 or 1 and R⁵ is selected from alkyl, aryl
 and fluoroalkyl; or R³ and R⁴ together form a saturated
 or unsaturated ring system Y-V-Z wherein Y and Z,
 25 independently of each other, are as defined for Z above
 and V is selected from C₁-C₃ alkylene or alkenylene,
 -N=, -N=N- and -N-R₇ wherein R₇ = H or alkyl and PG is
 a protecting group, such as alkyl, benzyl (Bn), 2-
 (trimethylsilyl)ethoxymethyl (SEM), methoxymethyl (MOM)
 30 or 2-methoxyethoxymethyl (MEM);


a compound of the general formula IV

35



wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl and R^6 is selected from alkyl, Bn, SEM, MEM, MOM and 2,2,2-trichloroethyl;

a compound of the general formula V




wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl and $N=N$; R^6 and PG are selected from alkyl, Bn, SEM, MEM and

MOM;

a compound of the general formula VI

5



10


wherein X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl;

15

20

a compound of the general formula VII

25




30

wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, halogen and cyano; R^4 is selected from RSO_2 and RCO wherein $R = C_1-C_5$ alkyl;

35

a compound of the general formula VIII

5




VIII

wherein R^1 and R^2 are the same or different and
 selected from H and alkyl; X is selected from
 10 alkylthio, halogen and cyano; R^3 is selected from RSO_2
 and RCO wherein $R = C_1-C_5$ alkyl;

and

15 a compound of the general formula IX

20



IX

wherein R^1 and R^2 are the same or different and
 selected from H and alkyl; R^3 , R^4 are the same or
 25 different and selected from halogen, methyl,
 fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from
 CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or
 1 and R^5 is selected from alkyl and fluoroalkyl; or R^3
 and R^4 together form a saturated ring system Y-V-Z
 30 wherein Y and Z, independently of each other, are as
 defined for Z above and V is selected from C_1-C_3
 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein R_7
 = H or alkyl.

35

Detailed description of the invention

The following definitions shall apply throughout the specification and the appended claims.

5

Unless otherwise stated or indicated, the term "alkyl" denotes a straight or branched lower alkyl group, preferably a C₁-C₆ alkyl. Examples of said lower alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, 10 iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl.

Unless otherwise stated or indicated, the term "aryl" denotes a phenyl, furyl or thienyl group in which the 15 ring is optionally further substituted by lower alkyl, lower alkoxy or halogen.

Unless otherwise stated or indicated, the term "alkylthio" denotes a straight or branched lower 20 alkylthio preferably a C₁-C₆ alkylthio. Examples of said lower alkylthio include methylthio, ethylthio, n-propylthio, iso-propylthio, n-butylthio, iso-butylthio, sec-butylthio, t-butylthio and straight- and branched-chain pentylthio and hexylthio.

25

Unless otherwise stated or indicated, the term "arylthio" denotes a phenylthio group in which the phenyl ring is optionally further substituted by lower 30 alkyl, lower alkoxy or halogen.

30

Unless otherwise stated or indicated, the term "aryloxy" denotes a phenoxy group in which the phenyl ring is optionally further substituted by lower alkyl, lower alkoxy or halogen.

35

Unless otherwise stated or indicated, the term "halogen" shall mean fluorine, chlorine, bromine or

iodine.


The best mode of carrying out the invention known at present is to use 4,6-dichloro-5-methylantranilic acid.

The compounds according to the present invention may be used in connection with prevention or treatment of neurodegeneration, especially in connection with conditions such as stroke, cerebral ischaemia, hypoxia, epilepsy and in neurodegenerative diseases such as Alzheimer's disease, multi-infarct dementia, Huntington's disease and the AIDS dementia complex.

Below the methods for the preparation of the compound of formula I will be described in detail.

Methods of preparation

Compounds of formula I




wherein R¹ and R² are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R³, R⁴ are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and Z-R⁵ wherein Z is selected from CH_n, NH_m, O, S, SO₂ and CO wherein n = 1 or 2; m = 0 or 1 and R⁵ is selected from alkyl, aryl and fluoroalkyl; or R³ and R⁴ together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z; are as defined for Z above and V is selected from C₁-C₃

alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl; may be prepared by one of the following methods.

5

Method A Compounds of formula I wherein R^1 and $R^2 = H$; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl; may be prepared from compounds of formula II

20



II


25

wherein X, R^3 and R^4 are as defined in formula I in method A, for example by reduction with H_2 and a catalyst such as Pd/C, Raney nickel or PtS_2 at atmospheric or elevated pressure in a suitable solvent such as EtOH or EtOAc. The reduction can also be accomplished by reaction with $SnCl_2$, $NH_2NH_2 \cdot H_2O$ or $Na_2S_2O_5$ in a suitable solvent such as EtOH.

35

Method B Compounds of the general formula I wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or

different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl; may be prepared from compounds of formula III




III

wherein R^1 , R^2 , X, R^3 and R^4 are as defined in formula I in method B and PG is selected from alkyl, Bn, SEM, MEM and MOM, by deprotection with for example a Lewis acid such as BBr_3 or trimethylsilyl iodide or with alkyl- or arylsNa or alkyl- or arylSLi followed by adjustment of the pH to obtain the 3-hydroxyanthranilic acid derivative. In the case where PG = SEM, deprotection may be performed using tetrabutylammonium fluoride (TBAF) or CsF in a suitable solvent such as N,N-dimethylpropylenurea (DMPU) or N,N-dimethylformamide (DMF) at elevated temperature. A benzyl group may be removed by hydrogenolysis using for example H_2 and Pd/C or PtS_2 as a catalyst. A 2,2,2-trichloroethyl group may be removed using Zn in acetic acid.

Method C Compounds of formula I wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and


selected from halogen, methyl, fluoroalkyl, cyano and
 Z-R⁵ wherein Z is selected from CH_n, NH_m, O, S, SO₂ and
 CO wherein n = 1 or 2; m = 0 or 1 and R⁵ is selected
 from alkyl, aryl and fluoroalkyl; or R³ and R⁴ together
 5 form a saturated or unsaturated ring system Y-V-Z
 wherein Y and Z, independently of each other, are as
 defined for Z above and V is selected from C₁-C₃
 alkylene or alkenylene, -N=, -N=N- and -N-R₇ wherein R₇
 = H or alkyl; may be prepared from compounds of formula
 10 IV



wherein R¹, R², X, R³ and R⁴ are as defined in formula
 I in method C and R⁶ is selected from alkyl, Bn, SEM,
 20 MEM, MOM and 2,2,2-trichloroethyl, by deesterifying
 with for example a base such as KOH in a suitable
 solvent such as MeOH at room temperature or at elevated
 temperature, or by alkyl- or arylSLi or alkyl- or
 arylSNa or with Me₃SiI followed by adjustment of the pH
 25 to obtain the 3-hydroxyanthranilic acid derivative. In
 the case where R⁶ = Bn, the carboxylic acid may be
 obtained by hydrogenolysis with for example H₂ and Pd/C
 or PtS₂. A 2,2,2-trichloroethylester may be cleaved
 with for example Zn in HOAc and a SEM-ester for example
 30 with TBAF in DMPU.

Method D Compounds of formula I wherein R¹ and R² are
 the same or different and selected from H and alkyl; X
 is selected from alkylthio, arylthio, aryloxy, halogen
 35 and cyano; R³, R⁴ are the same or different and
 selected from halogen, methyl, fluoroalkyl, cyano and
 Z-R⁵ wherein Z is selected from CH_n, NH_m, O, S, SO₂ and

CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl; may be prepared from compounds of formula V




wherein R^1 , R^2 , X, R^3 and R^4 are as defined in formula I in method D; PG and R^6 are selected from alkyl, Bn, SEM, MEM and MOM, by deesterification and deprotection with for example alkyl- or arylSLi, alkyl- or arylSNa or with Me_3SiI followed by adjustment of the pH to obtain the 3-hydroxyanthranilic acid derivative. In the case where PG and $R^6 = Bn$, the 3-hydroxyanthranilic acid derivative may be obtained by hydrogenolysis with for example H_2 and Pd/C or PtS_2 and if PG and $R^6 = SEM$, TBAF may be used.

Method E Compounds of formula I wherein $R^1 = alkyl$; $R^2 = H$ or alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and Z- R^5 wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$

and -N-R₇ wherein R₇ = H or alkyl; may be prepared from compounds of formula VI

5




VI

10 wherein X, R³ and R⁴ are as defined in formula I in method E, by reductive alkylation with for example an aldehyde corresponding to R¹ and a reducing agent such as NaCNBH₃ and HCl in a suitable solvent such as CH₃CN, H₂O or MeOH. Mono- and di-N-alkylated derivatives can
15 be separated for example by chromatography.

Method F Compounds of formula I wherein R¹ and R² are the same or different and selected from H and alkyl; X is selected from alkylthio, halogen and cyano; R³ is
20 selected from chloro, bromo and iodo; R⁴ is selected from alkoxy, alkyl, alkylthio, cyano, fluoroalkyl, halogen, RSO₂ and RCO wherein R = C₁-C₅ alkyl, may be prepared from compounds of formula VII

25




VII

30

wherein R¹, R², X and R⁴ are as defined in formula I in method F, by halogenation with for example Br₂, Cl₂ or ICl in acetic acid at room- or elevated temperature. Alternatively, VII could be halogenated with Br₂ or I₂
35 and mercuric trifluoroacetate in trifluoroacetic acid at room- or elevated temperature.

Method G Compounds of formula I wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, halogen and cyano; R^3 is selected from alkoxy, alkyl, alkylthio, cyano, fluoroalkyl, halogen, RSO_2 and RCO wherein $R = C_1-C_5$ alkyl; R^4 is selected from chloro, bromo and iodo, may be prepared from compounds of formula VIII


10



15 wherein R^1 , R^2 , X and R^3 are as defined in formula I in method G, by halogenation for example according to method F.

20 Method H Compounds of formula I wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from bromo, chloro and iodo; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl and fluoroalkyl; or R^3 and R^4 together form a saturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl; 30 may be prepared from compounds of formula IX

35




wherein R^1 , R^2 , R^3 and R^4 are as defined in formula I in method H, by halogenation for example according to method F.

5

Intermediates

Method II:a Compounds of formula II wherein X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 and R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 , R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl; may be prepared from compounds of formula X

20



25


wherein X, R^3 and R^4 are as defined in formula II in method II:a, by nitration using for example HNO_3 in a solvent such as CH_3NO_2 , CH_2Cl_2 or H_2O or a mixture of HNO_3 and H_2SO_4 .

30

Method II:b Compounds of formula II wherein X is selected from chloro, bromo and iodo; R^3 and R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl and fluoroalkyl; or


35

R^3, R^4 together form a saturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl may be prepared from compounds of formula XI



wherein R^3 and R^4 are as defined in formula II in method II:b, by halogenation for example according to method F.


Method III:a Compounds of formula III wherein R^1 and $R^2 = H$; X is selected from halogen and aryloxy; R^3 and R^4 are the same or different and selected from halogen, methyl, fluoroalkyl and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O and SO_2 wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl; and PG is selected from alkyl, Bn, MEM and MOM; may be prepared from compounds of formula XII



wherein X, R³, R⁴ and PG are as defined in formula III in method III:a by reacting a compound of formula XII with for example H₂O₂ and NaOH in a suitable solvent such as water or dioxan. The pH is then adjusted to
 5 obtain the 3-hydroxyanthranilic acid derivative.

Method III:b Compounds of formula III wherein R¹ and R² = H; X is selected from alkylthio, chloro and fluoro; R³ and R⁴ are the same or different and selected from
 10 chloro, fluoro, methyl, fluoroalkyl and Z-R⁵ wherein Z is selected from CH_n, N, O and S wherein n = 1 or 2; and R⁵ = alkyl; or R³ and R⁴ together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z; are as defined for Z above and V is selected from C₁-C₃
 15 alkylene or alkenylene, -N=, -N=N- and -N-R₇ wherein R₇ = H or alkyl; and PG is selected from alkyl, SEM, MEM and MOM; may be prepared from compounds of formula XIII

20




XIII

25 wherein X, R³, R⁴ and PG are as defined in formula III in method III:b; DMG = C(O)OtBu, CO₂tBu or COCF₃; W = H or Br for example by reaction with alkylolithium in a suitable solvent such as tetrahydrofuran (THF) at low temperature. The aryllithium derivative is then reacted
 30 with CO₂(s), acidified and the DMG group is removed by aqueous HCl at elevated temperature.

Method IV:a Compounds of formula IV wherein R¹ and R² are the same or different and selected from H and
 35 alkyl; X is selected from alkylthio, halogen and cyano; R³ is selected from chloro, bromo and iodo; R⁴ is selected from alkoxy, alkyl, alkylthio, cyano,


fluoroalkyl, halogen, RSO_2 and RCO wherein $\text{R} = \text{C}_1\text{-C}_5$ alkyl; R^6 is for example selected from SEM, MEM, MOM and 2,2,2-trichloroethyl; may be prepared from compounds of formula XIV



XIV

wherein R^1 , R^2 , X , R^4 and R^6 are as defined in formula IV in method IV:a; by halogenation for example according to method F.

Method IV:b Compounds of formula IV wherein $\text{R}^1 = \text{H}$ or alkyl; $\text{R}^2 = \text{alkyl}$; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 and R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and Z-R^5 wherein Z is selected from CH_n , NH_m , O , S , SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 , R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z , independently of each other, are as defined for Z above and V is selected from $\text{C}_1\text{-C}_3$ alkylene or alkenylene, $-\text{N}=\text{}$, $-\text{N}=\text{N}-$ and $-\text{N}-\text{R}_7$ wherein $\text{R}_7 = \text{H}$ or alkyl; R^6 is selected from SEM, MEM, MOM and 2,2,2-trichloroethyl; may be prepared from compounds of formula XV




XV

wherein X , R^3 , R^4 and R^6 are as defined in formula IV in

method IV:b; by alkylation for example according to method E.

Method V Compounds of formula V wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, chloro, fluoro and cyano; R^3 , R^4 are the same or different and selected from chloro, fluoro, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 , R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl; R^6 and PG are selected from alkyl and Bn; may be prepared from compounds of formula XVI




25 wherein R^1 , R^2 , X, R^3 , R^4 and PG are as defined in formula V in method V and $W = Br$, I or OSO_2CF_3 by reacting a compound of formula XVI with for example a mixture of $Pd(OAc)_2$, CO, 1,3-bis(diphenylphosphino)-propane and an alcohol corresponding to R^6 in a

30 suitable solvent such as DMF or dioxan containing a base such as Et_3N .

Method VI Compounds of formula VI wherein X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 and R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n =$


35

- 1 or 2; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 , R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1 - C_3 alkylene or alkenylene, -N=, -N=N- and -N- R_7 wherein $R_7 = H$ or alkyl; may be prepared from compounds of formula XVII



- 15 wherein X, R^3 and R^4 are as defined in formula VI in method VI and R^6 and PG are selected from alkyl, Bn, SEM, MEM and MOM; by deesterifying and deprotecting for example according to method D.

- 20 Method VII:a Compounds of formula VII wherein R^1 and $R^2 = H$; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; $R^4 = RSO_2$ or RCO wherein $R = C_1$ - C_5 alkyl; may be prepared from compounds of formula XVIII




- 30 wherein X and R^4 are as defined in formula VII in method VII:a; by reduction for example according to method A.

- 35 Method VII:b Compounds of formula VII wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy,

halogen and cyano; $R^4 = RSO_2$ or RCO wherein $R = C_1-C_5$ alkyl may be prepared from compounds of formula XIX


5



10 wherein R^1 , R^2 , X and R^4 are as defined in formula VII in method VII:b and R^6 and PG are selected from alkyl, Bn, SEM, MEM and MOM; by deesterifying and deprotecting for example according to method D.

15 Method VIII Compounds of formula VIII wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from chloro, bromo and iodo; R^3 is selected from RSO_2 and RCO wherein $R = C_1-C_5$ alkyl, may be prepared from compounds of formula XX

20




25

wherein R^1 , R^2 and R^3 are as defined in formula VIII in method VIII, by halogenation for example according to method F.

30

Method IX:a Compounds of formula IX wherein R^1 and R^2 are the same or different and selected from H and alkyl; R^3 is selected from chloro, bromo and iodo; R^4 is selected from alkoxy, alkyl, alkylthio, cyano, fluoroalkyl, halogen, RSO_2 and RCO , may be prepared from compounds of formula XXI


35



5

wherein R^1 , R^2 and R^4 are as defined in formula IX in method IX:a, by halogenation for example according to method F.

- 10 Method IX:b Compounds of the formula IX wherein R^1 and R^2 are the same or different and selected from H and alkyl; R^3 and R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 , R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl; may be prepared from compounds of formula XXII
- 15
- 20



25

- wherein R^1 , R^2 , R^3 and R^4 are as defined in formula IX in method IX:b and R^6 is selected from alkyl, Bn, SEM, MEM, MOM and 2,2,2-trichloroethyl, by deesterifying for example according to method C.
- 30

35 Working examples

Example 1 (Method B)

Preparation of 4-Chloro-5,6-dimethyl-3-hydroxyanthranilic acid

2-Chloro-3,4-dimethyl-6-nitrophenol

5

4,5-Dimethyl-2-nitrophenol¹ (7.00 g, 41.9 mmol) was dissolved in CHCl_3 (300 mL) and flushed with argon. Chlorine, dissolved in CHCl_3 (84.8 mL, 0.99 M, 83.7 mmol) was added and the solution was stirred at room temperature for 26 h, protected from light. The solvent, HCl and excess of Cl_2 were evaporated (protected from light) and the residue was partitioned between CH_2Cl_2 (400 mL) and brine (100 mL). Drying (MgSO_4) and evaporation of the solvent gave 8.9 g of a crude product. Purification by flash column chromatography (SiO_2 , CHCl_3 -Hexane 1:1) afforded the title compound (6.47 g). Mp: 62-63°C; ^1H NMR ($\text{DMSO}-d_6$): δ 11.5 (br, OH), 7.80 (s, 1 H), 2.34 (s, 3 H), 2.27 (s, 3 H); ^{13}C NMR ($\text{DMSO}-d_6$): δ 146.86, 143.84, 134.06, 128.85, 123.73, 122.94, 19.37, 17.36; MS (EI, 70 eV): m/z (rel.int.) 203/201 (M^+ , 37/100), 91 (88).

1-Benzyloxy-2-chloro-3,4-dimethyl-6-nitrobenzene

2-Chloro-3,4-dimethyl-6-nitrophenol (6.44 g, 31.9 mmol) was dissolved in dry DMF (105 mL) and flushed with argon. Benzyl bromide (4.17 mL, 35.1 mmol) and K_2CO_3 (13.24 g, 95.7 mmol) were added. The reaction mixture was stirred at room temperature for 8 h (protected from light) and filtered. Water (5 mL) was added and the solvent was co-evaporated with xylene (2x150 mL) and CH_2Cl_2 (100 mL). The residue was mixed with CHCl_3 (100 mL), filtered and after evaporation of the solvent 10.8 g of crude product remained. Purification by flash column chromatography (SiO_2 , CHCl_3 -Hexane 1:1) gave the title compound (8.44 g). Mp: 74-75°C; ^1H NMR ($\text{DMSO}-d_6$): δ 7.80 (s, 1 H), 7.48-7.37 (m, 5 H), 5.06 (s, 2 H),

2.37 (s, 3 H), 2.34 (s, 3 H); ^{13}C NMR (DMSO- d_6): δ 145.24, 142.22, 142.08, 135.73, 134.73, 129.61, 128.39, 128.37, 128.35, 123.64, 75.74, 19.74, 17.13; MS (EI, 70 eV): m/z (rel.int.) 293/291 (M^+ , 0.08/0.37), 187/185 (8/24), 91 (100).

6-Amino-1-benzyloxy-2-chloro-3,4-dimethylbenzene

1-Benzyloxy-2-chloro-3,4-dimethyl-6-nitrobenzene (3.00 g, 10.3 mmol) was dissolved in MeOH (420 mL) and cooled to +2°C. Copper(I) chloride (6.11g, 30.8 mmol) was added followed by KBH_4 (3.88 g, 72.0 mmol) portionwise added at +2 to +4°C during 1.5 h. The reaction mixture was stirred at +2°C for 1 h and more KBH_4 (400 mg, 7.41 mmol) was added. After 1 h at +2°C additional KBH_4 (120mg, 2.22 mmol) was added and the stirring was continued for another 20 min. Filtration and evaporation of the solvent gave a residue which was extracted between EtOAc (400 mL) and water (75 mL). Drying (MgSO_4) and evaporation afforded 2.94 of crude product. Purification by flash column chromatography (SiO_2 , CHCl_3) yielded the title compound (2.14 g). Mp: 57-58°C; ^1H NMR(DMSO- d_6): δ 7.54 (d, $J=6.5$ Hz, 2 H), 7.42-7.34 (m, 3 H), 6.52 (s, 1 H), 4.83 (s, 2 H), 4.79 (s, 2 H), 2.12 (s, 6 H); ^{13}C NMR (DMSO- d_6): δ 140.00, 138.91, 137.30, 133.00, 128.27, 128.22, 127.91, 127.33, 121.23, 115.35, 72.73, 20.24, 15.45; MS (EI, 70 eV): m/z (rel.int.) 286/284 ($\text{M}+23$, 42/100).

1-Benzyloxy-2-chloro-3,4-dimethyl-6-(E/Z)-isonitrosoacetamidobenzene

6-Amino-1-benzyloxy-2-chloro-3,4-dimethylbenzene (2.14 g, 8.19 mmol) was dissolved in DMF (60 mL) and water (2 mL). Concentrated HCl (683 μL , 8.19 mmol) and chloral hydrate (1.49 g, 9.00 mmol) were added and the flask was placed in an oil-bath preheated to 105°C. After 2

min $\text{NH}_2\text{OH}\cdot\text{HCl}$ (2.28 g, 32.8 mmol), dissolved in water (4 mL) was added and the reaction mixture was stirred at 100°C for 1 h, protected from light and for 15 min at room temperature. Evaporation and co-evaporation with xylene and CH_2Cl_2 gave a residue which was extracted between EtOAc and water. After drying the organic phase (MgSO_4) and evaporation of the solvent 3.2 g of crude product was obtained. Purification by flash column chromatography (SiO_2 , EtOAc- CHCl_3 1:10) afforded an E/Z mixture of the title compound (1.278 g). ^1H NMR ($\text{DMSO}-d_6$): δ 12.33 and 9.71 (2 s, 1 H), 9.20 and 8.27 (2 s, 1 H), 7.91 and 7.83 (2 s, 1 H), 7.60 (s, 1H), 7.65-7.36 (m, 5 H), 4.90 and 4.87 (2 s, 2 H), 2.26-2.23 (m, 6 H); ^{13}C NMR ($\text{DMSO}-d_6$): δ 160.18, 159.99, 143.40, 143.06, 136.55, 136.08, 133.40, 133.26, 130.97, 130.39, 129.70, 129.44, 128.69, 128.40, 128.36, 128.28, 128.19, 128.11, 128.03, 127.37, 127.25, 121.51, 121.21, 74.66, 74.18, 20.32, 16.08; MS (EI, 70 eV): m/z (rel.int.) 334/332 (M^+ , 4/12), 172/170 (12/51), 91(100).

7-Benzyloxy-6-chloro-1H-4,5-dimethylbenzindole-2,3-dione

Concentrated H_2SO_4 (6 mL) was heated to 80°C and 1-benzyloxy-2-chloro-3,4-dimethyl-6-(E/Z)-isonitrosoacetamidobenzene (700 mg, 2.10 mmol) was added. The reaction mixture was stirred at 80°C for 10 min and poured into ice-water (200 mL). Extraction with EtOAc (200 mL), drying (MgSO_4) and evaporation gave a residue 376 mg was dissolved in dry DMF (5 mL) and BnBr (275 μL , 2.30 mmol) and K_2CO_3 (318 mg, 2.30 mmol) were added. The reaction mixture was stirred for 30h at room temperature protected from light. Filtration, addition of HOAc (1 mL), co-evaporation with xylene (3x100 mL), mixing the residue with HOAc (500 μL) and CH_2Cl_2 -MeOH (50:1, 15 mL), filtration again and evaporation gave

741 mg of crude product. Purification by repeated flash column chromatography (SiO_2 , CH_2Cl_2 -MeOH-gradient) gave the title compound (13 mg). ^1H NMR ($\text{DMSO}-d_6$): δ 11.42 (s, 1 H), 7.57 (d, $J=6.2\text{Hz}$, 2 H), 7.42-7.35 (m, 3 H), 4.92 (s, 2 H), 2.44 (s, 3 H), 2.22 (s, 3H); ^{13}C NMR ($\text{DMSO}-d_6$): δ 184.30, 159.33, 141.87, 137.02, 136.98, 136.26, 135.41, 130.15, 128.84, 128.28, 128.18, 115.64, 74.63, 15.26, 14.20; MS (EI, 70 eV): m/z (rel.int.) 317/315 (M^+ , 3/7), 91 (100).

3-Benzylloxy-4-chloro-5,6-dimethylanthranilic acid

7-Benzylloxy-6-chloro-1H-4,5-dimethylbenzindole-2,3-dione (13 mg, 0.04 mmol) was mixed with dioxan (500 μL) and NaOH (200 μL , 0.68 M, 0.14 mmol) was added. The solution was cooled to $+10^\circ\text{C}$ and H_2O_2 (4 μL , 30 %, 0.12 mmol) dissolved in NaOH (410 μL , 0.68 M, 0.27 mmol) was added. More H_2O_2 (1 μL , 0.03 mmol) was added after 2 min and the reaction mixture was stirred for 1 h at room temperature. Hydrogen peroxide (2 μL , 0.06mmol) was added and after 20 min some of the solvent was removed by a stream of N_2 before HOAc (38 μL , 0.66 mmol) was added precipitating a crude orange product. As much dioxan as possible was removed before the slurry was partitioned between EtOAc (3 mL) and water (500 μL), the aqueous phase was extracted with EtOAc (500 μL) and the combined organic phase was washed with brine (500 μL) and dried (MgSO_4). After evaporation of the solvent the residue was dissolved in dioxan (100 μL) and NaOH (200 μL , 0.68 M, 0.14 mmol), cooled to $+10^\circ\text{C}$ and reacted with H_2O_2 (4 μL , 0.12 mmol) in NaOH (400 μL , 0.27 mmol) for 3 h at $+10^\circ\text{C}$ to room temperature. Work-up as described above gave the title compound (11 mg). ^1H NMR ($\text{DMSO}-d_6$): δ 7.55 (d, $J=7.0\text{ Hz}$, 2 H), 7.43-7.35 (m, 3 H), 4.82 (s, 2 H), 2.21 (s, 3 H), 2.19 (s, 3 H); MS (EI, 70 eV): m/z (rel.int.) 307/305 (M^+ , 7/19), 216/214 (26/75), 198/196(14/44), 91(100).

4-Chloro-5,6-dimethyl-3-hydroxyanthranilic acid

3-Benzoyloxy-4-chloro-5,6-dimethylantranilic acid (10 mg, 0.03 mmol) was dissolved in EtOH (1.5 mL) and 10 %
5 Pd/C (2 mg) was added. Hydrogenation at room temperature and atmospheric pressure for 5 h, filtration, evaporation yielded 7 mg of crude product. Purification by preparative HPLC (Lichrosorb-C₁₈, MeOH-Phosphate buffer (pH3) 50:50) adjusting the pH to 5
10 with NaHCO₃(aq), concentrating by a stream of N₂, extracting with EtOAc (3x5 mL), washing the organic phase with brine, drying (MgSO₄) and evaporating afforded the title compound (3 mg). ¹H NMR (DMSO-d₆): δ 3.3 (br, OH), 3.16 (s, 2 H), 2.16 (s, 3 H), 2.15 (s, 3
15 H); ¹³C NMR (DMSO-d₆): δ 169.92, 137.87, 135.16, 126.38, 123.51, 121.39, 117.31, 17.72, 15.95; MS (EI, 70 eV): m/z (rel.int.) 217/215 (M⁺, 21/63), 199/197 (20/59), 171/169 (37/100).

20

Example 2 (Method B)Preparation of 7-Amino-5-chloro-8-carboxy-6-hydroxytetralin

25

5-Chloro-6-hydroxy-7-nitrotetralin

6-Hydroxy-7-nitrotetralin² (2.44 g, 12.6 mmol) was dissolved in CHCl₃ (290 mL) and the solution was flushed
30 with argon. Chlorine, dissolved in CHCl₃ (25.6 mL, 0.99 M, 25.3 mmol) was added and the solution was stirred for 6 h at room temperature, protected from light. The solvent, HCl and excess of Cl₂ were evaporated protected from light giving 3.02g of crude product.
35 Purification by flash column chromatography (SiO₂, CHCl₃-Hexane 1:1) gave the title compound (2.29 g). ¹H NMR (DMSO-d₆): δ 10.62 (br, 1 H), 7.71 (s, 1 H), 2.75-

2.69 (m, 4 H), 1.77-1.64 (dm, 4H); ^{13}C NMR (DMSO- d_6): δ 146.30, 143.58, 134.59, 129.68, 123.42, 122.79, 28.26, 27.91, 21.69, 21.62; MS (EI, 70 eV): m/z (rel.int.) 229/227 (M^+ , 32/100, 101/99 (12/36), 117/115 (23/50).

5

6-Benzyloxy-5-chloro-7-nitrotetralin

5-Chloro-6-hydroxy-7-nitrotetralin (2.28 g, 10.0 mmol) was dissolved in dry DMF (40 mL) and flushed with argon. Benzyl chloride (11.5 mL, 100.0 mmol) $n\text{-Bu}_4\text{NI}$ (95 mg, 0.25 mmol) and K_2CO_3 (41.5 g, 30.0 mmol) were added. The reaction mixture was stirred for 24 h at room temperature, protected from light. The salts were filtered off and the solvent and excess of BnCl were co-evaporated with xylene (3x200mL) and CH_2Cl_2 (200 mL), followed by vacuum-drying. The crude product (5.8 g) was purified by flash column chromatography (SiO_2 , CHCl_3 -Hexane 1:1) and afforded the title compound (2.20 g). Mp 80-82°C; ^1H NMR (DMSO- d_6): δ 7.73 (s, 1 H), 7.48-7.37 (m, 5 H), 5.06 (s, 2 H), 2.79-2.75 (m, 4 H), 1.79-1.69 (dm, 4 H); ^{13}C NMR (DMSO- d_6): δ 144.81, 142.14, 135.79, 135.56, 129.55, 128.42, 123.40, 106.20, 105.51, 75.80, 28.63, 27.65, 21.55, 21.36; MS (TSP): m/z (rel.int.) 337/335 ($\text{M}+\text{NH}_4$, 30/100).

25

7-Amino-6-benzyloxy-5-chlorotetralin

Methanol (430 mL) was added to 6-benzyloxy-5-chloro--nitrotetralin (2.56 g, 8.33 mmol) and the mixture was cooled to +1°C. Copper(I) chloride (4.95 g, 25.0 mmol) was added followed by portionwise addition of KBH_4 (3.15 g, 58.3 mmol) during 1 h 10 min at +2°C. After 3.5 h more KBH_4 (100 mg, 1.85 mmol) was added and after 7.5h at +2°C, the reaction mixture was filtered and the solvent evaporated. The residue was extracted between EtOAc and water and the organic phase was washed with brine (50 mL), dried (Na_2SO_4) and evaporated giving

35

2.47 g of crude product. Purification by flash column chromatography (SiO_2 , CHCl_3) yielded the title compound (1.82 g). ^1H NMR ($\text{DMSO}-d_6$): δ 7.55 (dd, $J_1=1.6$ Hz, $J_2=8.1$ Hz, 2 H), 7.41-7.34 (m, 3 H), 6.42 (s, 1 H), 4.84 (s, 2 H), 4.79 (s, 2 H), 2.58-2.52 (m, 4 H), 1.71-1.60 (m, 4 H); ^{13}C NMR ($\text{DMSO}-d_6$) δ 140.10, 139.29, 137.29, 133.96, 128.29, 128.23, 127.93, 126.99, 121.84, 113.96, 29.03, 26.25, 22.68, 22.35; MS (TSP): m/z (rel.int.) 290/288 ($M+1$, 27/100).

6-Benzoyloxy-5-chloro-7-(E/Z)-isonitroso-acetamidotetralin

7-Amino-6-benzoyloxy-5-chlorotetralin (1.84 g, 6.41 mmol) was dissolved in DMF (80 mL) and water (8 mL). The solution was flushed with argon and HCl (530 μL , 12 M, 6.41 mmol) was added followed by chloral hydrate (1.17 g, 7.05 mmol). The flask was placed in an oil-bath, preheated to 110°C and a solution of $\text{NH}_2\text{OH}\cdot\text{HCl}$ (1.78 g, 25.6 mmol) in water (8 mL) was added under stirring. After 1 h at 100°C followed by 1 h at room temperature, the solvents were co-evaporated with xylene (3x100 mL) and CH_2Cl_2 (100 mL). The residue was extracted between EtOAc and water and the organic phase was washed with brine (50 mL), dried (Na_2SO_4) and evaporated yielding 2.63 g of crude product.

Purification by flash column chromatography (SiO_2 , EtOAc- CHCl_3 1:5) afforded an E/Z mixture of the title compound. ^1H NMR ($\text{DMSO}-d_6$): δ 12.33 and 9.72 (2 s, 1 H), 9.20 and 8.28 (2 s, 1 H), 7.84 and 7.72 (2 s, 1 H), 7.60 (s, 1 H), 7.57-7.37 (m, 5 H), 4.90 and 4.88 (2 s, 2 H), 2.71-2.65 (m, 4 H), 1.75-1.68 (m, 4 H); ^{13}C NMR ($\text{DMSO}-d_6$): δ 160.26, 160.02, 143.45, 143.00, 136.60, 136.13, 134.37, 134.26, 131.20, 130.63, 129.81, 129.52, 128.75, 128.33, 128.16, 128.09, 127.04, 120.68, 120.33, 74.75, 74.28, 29.13, 26.74, 22.17, 22.00; MS (TSP): m/z (rel.int.) 361/359 ($M+1$, 28/100).

9-Benzyloxy-8-chloro-1H-4,5,6,7-tetrahydro[e]benzindole-2,3-dione

Concentrated H₂SO₄ (5 mL) was heated to 60°C and 6-benzyloxy-5-chloro-7-(E/Z)-isonitrosoacetamidotetralin (500 mg, 1.39 mmol) was added portionwise during 1 min. The reaction mixture was stirred at 60°C for 10 min and poured on crushed ice (50 mL). Extraction with EtOAc (200 mL), drying (Na₂SO₄) and evaporation gave a residue 317 mg which was dissolved in dry DMF (3 mL) and flushed with argon. Benzyl bromide (165 µL, 1.39 mmol) and K₂CO₃ (192 mg, 1.39 mmol) were added and the reaction mixture was stirred at room temperature for 18 h. Methanol (3 mL) was added, the salts were filtered off, and the solvents were co-evaporated with xylene (2x30 mL) followed by drying in vacuum. Acetic acid (0.3 mL, 5.2 mmol) was added to the crude product and filtration through SiO₂ using (EtOAc-MeOH 20:1) as eluent followed by evaporation of the solvents gave a dark residue (330 mg). Purification by repeated flash column chromatography (SiO₂, CH₂Cl₂-MeOH 50:1) afforded the title compound (56 mg). ¹H NMR (DMSO-d₆): δ 11.40 (s, 1 H), 7.58 (d, J=7.3 Hz, 2 H), 7.42-7.36 (m, 3 H), 4.90 (s, 2 H), 2.92 (t, J=7.3 Hz, 2 H), 2.63 (t, J=6.0 Hz, 2 H), 1.74-1.66 (m, 4 H); ¹³C NMR (DMSO-d₆): δ 183.83, 159.39, 142.27, 137.26, 137.05, 136.25, 136.20, 129.90, 128.76, 128.22, 128.13, 114.74, 74.63, 26.68, 25.42, 21.71, 20.77; MS (EI, 70 eV) m/z(rel.int.) 343/341 (M⁺, 5/15), 91 (100).

7-Amino-6-benzyloxy-8-carboxy-5-chlorotetralin

9-Benzyloxy-8-chloro-1H-4,5,6,7-tetrahydro[e]benzindole-2,3-dione (51 mg, 0.15 mmol) was mixed with NaOH(aq) (890 µL, 0.68 M, 0.60 mmol), water (460 µL) was added and the slurry was cooled to +10°C. Hydrogen peroxide (46 µL, 30 %, 0.45 mmol) was mixed with

NaOH(aq) (1.33 mL, 0.68 M, 0.90 mmol) and added to the slurry. After 2 min more H₂O₂ (20 µL, 30 %, 0.20 mmol) was added and the reaction mixture was stirred for 1 h at room temperature. Dioxan (1.5 mL) was added to the
5 slurry followed by additional H₂O₂ (20 µL, 30 %, 0.20 mmol) and stirred for another 2 h. The solution was filtered diluted with water (2 mL) and HOAc (100 µL, 1.75 mmol) was added precipitating the product. After stirring the slurry for 30 min EtOAc (40 mL) and water
10 (10 mL) were added. Extracting the aqueous phase with EtOAc (10 mL) and washing the combined organic layer with brine (10 mL), drying (Na₂SO₄) and evaporating yielded the title compound (35 mg). ¹H NMR (DMSO-d₆): δ 7.56 (d, J=7.0 Hz, 2 H), 7.43-7.36 (m, 3 H), 4.84 (s, 2
15 H) 3.3 (br, NH, OH), 2.73 (m, 2 H), 2.59 (m, 2 H), 1.70-1.61 (m, 4 H); ¹³C NMR (DMSO-d₆): δ 169.29, 139.87, 139.47, 136.83, 133.13, 129.46, 128.28, 128.25, 128.05, 122.28, 116.49, 73.08, 28.08, 26.76, 22.17, 22.04; MS (EI, 70 eV): m/z (rel.int.) 333/331 (M⁺,
20 7/18), 224/222 (22/63), 91 (100).

7-Amino-5-chloro-8-carboxy-6-hydroxytetralin

7-Amino-6-benzyloxy-8-carboxy-5-chlorotetralin (33 mg, 0.10 mmol) was dissolved in EtOH (3 mL) and 5 % Pd/C (4
25 mg) was added. Hydrogenation at room temperature and atmospheric pressure for 2 h, filtration, evaporation and vacuum-drying gave the title compound (21 mg). Mp: 147°C (dec); ¹H NMR (DMSO-d₆): δ 7.9 (br, NH, OH), 2.66
30 (t, J=6.0 Hz, 2 H), 2.54 (t, J=6.7 Hz, 2 H), 1.70-1.64 (m, 2 H), 1.63-1.57 (m, 2 H); ¹³C NMR (DMSO-d₆): δ 169.73, 138.12, 136.45, 128.13, 123.32, 121.36, 115.15, 27.86, 26.91, 22.45, 22.25; MS (EI, 70 eV):
m/z (rel.int.) 243/241 (M⁺, 21/65), 225/223 (35/100),
35 197/195 (61/100).

Example 3 (Method A)Preparation of 4,6-dichloro-3-hydroxy-5-methylantranilic acid

5

2,4-Dichloro-5-methoxy-3-methylphenyl triflate

2,4-Dichloro-5-methoxy-3-methylphenol³ (7.73 g, 37.3 mmol) was dissolved in CH₂Cl₂ (180 mL) and flushed with argon. Triethylamine (10.4 mL, 74.7 mmol) and DMAP (10 mg, 0.08 mmol) were added. The solution was cooled to -78°C and trifluoromethane sulfonic anhydride (9.4 mL, 56.0 mmol) was added dropwise during 3 min. After 10 min at -78°C the reaction vessel was placed in an ice-bath and the stirring continued for additional 10 min. Methylene chloride (200 mL) and H₂O (150 mL) were added. The aqueous phase was extracted with CH₂Cl₂ (150 mL) and the combined organic phase was washed with brine (100 mL) and dried (MgSO₄). Evaporation of the solvent gave 20 g of a crude product. Filtration through SiO₂ using CH₂Cl₂ as the eluent followed by flash column chromatography (SiO₂, EtOAc-Hexane 1:3) afforded 12.3 g of the pure title compound. Mp: 74°C; ¹H NMR(DMSO-d₆) : δ 7.30 (s, 1H), 3.92 (s, 3H), 2.49 (s, 3H); ¹³C NMR (DMSO-d₆) : δ 154.23, 143.90, 136.95, 122.78, 118.07, 118.04 (q, d = 321 Hz), 105.36, 57.22, 18.01; MS (EI, 70eV); m/z (rel.int.) 340/338 (M⁺, 47/64), 207/205 (27/41), 179/177 (64/100).

30 Methyl 2,4-dichloro-5-methoxy-3-methylbenzoate

2,4-Dichloro-5-methoxy-3-methylphenyl triflate (7.60 g, 22.4 mmol) was dissolved in dioxan (75 mL), 1,3-bis(diphenylphosphino)propane (371 mg, 0.90 mmol) and palladium acetate (202 mg, 0.90 mmol) were added. After flushing with CO, Et₃N (6.90 mL, 49.4 mmol) and MeOH (23 mL) were added. Reaction with CO at 70°C and at

atmospheric pressure for 25°C, filtration and evaporation, of the solvent partition of the residue between Et₂O (350 mL) and 3 M NH₃ (150 mL), extraction of the aqueous layer with Et₂O (2 x 150 mL) followed by washing the combined organic phase with brine (150 mL), drying (MgSO₄), evaporation of the solvent gave a crude product. Filtration through SiO₂ using EtOAc as the eluent gave 5.2 g of a product which was purified by flash column chromatography (SiO₂, EtOAc-Hexane 1:3) to yield 4.18 g of the title compound. Mp : 74°C; ¹H NMR(DMSO-d₆) : δ 7.33 (s, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 2.45 (s, 3H) ; ¹³C NMR (DMSO-d₆) : δ 165.69, 153.26, 136.09, 130.46, 125.22, 122.95, 110.78, 56.64, 52.72, 17.86; MS (EI, 70eV): m/z (rel.int.) 250/248 (M⁺, 53/80), 219/217 (66/100), 191/189 (8/12).

2,4-Dichloro-5-hydroxy-3-methylbenzoic acid

Methyl 2,4-dichloro-5-methoxy-3-methylbenzoate (238 mg, 0.96 mmol) was dissolved in MeOH (30 mL) and flushed with argon. Potassium hydroxide (308 mg, 4.78 mmol) was added and the reaction mixture was stirred at 50°C for 19 h. The solvent was evaporated and the residue was dried in vacuum. Hydrobromic acid (30 mL, 48%, aq) was added and the mixture was heated to 110°C. After 3 days most of the HBr was removed by vacuum-distillation. The crude product was mixed with H₂O (10 mL), concentrated NH₃ (1 mL) and EtOAc (40 mL) were added, the aqueous phase (pH 1) was extracted with EtOAc (2x20 mL) and the combined organic phase was washed with brine (10 mL) and dried (MgSO₄). Evaporation of the solvent gave 202 mg of the title compound. ¹H NMR (DMSO-D₆): δ 10.68 (br, 1H), 7.15 (s, 1H), 2.42 (s, 3H); ¹³C NMR (DMSO-d₆): δ 166.68, 151.82, 135.87, 131.24, 123.70, 121.17, 114.36, 17.93; MS (EI, 70eV): m/z (rel.int.) 222/220 (M⁺, 56/100), 205/203 (36/59), 185(26).

4,6-Dichloro-3-hydroxy-5-methyl-2-nitrobenzoic acid

2,4-Dichloro-5-hydroxy-3-methylbenzoic acid (90 mg, 0.41 mmol) was mixed with CH_3NO_2 (9 mL) and heated to 40 °C. To the solution was added HNO_3 (20 μL , 90%, 0.43 mmol) and the reaction mixture was stirred at room temperature for 4h. Evaporation of the solvent followed by vacuum-drying over KOH gave 112 mg of a crude product. Purification by flash column chromatography (SiO_2 , EtOAc-HOAc 30:1) afforded 79 mg of the title compound. Mp: 199°C (dec); ^1H NMR ($\text{DMSO}-d_6$): δ 2.45 (s, 3H); ^{13}C NMR ($\text{DMSO}-d_6$): δ 164.27, 147.05, 139.61, 136.27, 128.35, 126.46, 118.87, 18.62; MS (EI, 70eV): m/z (rel.int.) 267/265 (M^+ , 66/100), 249/248 (67/85), 205/203 (28/54).

4,6-Dichloro-3-hydroxy-5-methylanthranilic acid

4,6-Dichloro-3-hydroxy-5-methyl-2-nitrobenzoic acid (69 mg, 0.26 mmol) was dissolved in HOAc (10 mL), 10% Pd/C (10 mg) and concentrated HCl (33 μ , 0.39 mmol) were added. Hydrogenation at room temperature and at atmospheric pressure for 2 h gave a slurry to which methanol (5 mL) was added and the catalyst was filtered off. Evaporation of the solvent, co-evaporation with toluene (10 mL) followed by vacuum-drying over KOH gave 63 mg of a crude product. Purification by flash column chromatography (SiO_2 , EtOAc-HOAc 45:1) yielded 55 mg of the title compound. Mp: 192°C (dec); ^1H NMR ($\text{DMSO}-d_6$): δ 2.27 (s, 3H); ^{13}C NMR ($\text{DMSO}-d_6$): δ 167.43, 139.25, 136.01, 122.90, 121.26, 120.37, 116.89, 16.96; MS (EI, 70eV): m/z (rel.int.) 237/235 (M^+ , 45/79), 219/217 (37/64), 191/189 (60/100).

- References
1. Diepolder E Chem. Ber. 42, 2916, 1909
 2. Chudozilov L. K Collect. Czech. Commun
1, 304, 1929
 3. Calam CT, J. Chem. Soc., 280, 282,
1939

Pharmacological method

10 Materials

[Carboxy-¹⁴C]3-hydroxyanthranilic acid (6 mCi/mmol) was received from Drs. E. Shaskan and L. Spitznagle (University of Connecticut, Farmington, CT, U.S.A.).

- 15 [³H]QUIN was obtained from the Nuclear Research Center (Negev, Israel). All other chemicals and reagents were obtained from commercial suppliers.

Tissue preparations

20

For routine assays, male Sprague-Dawley rats (150-200g) were killed by decapitation and their brains rapidly dissected onto ice. Whole forebrains or individual CNS regions were sonicated in four volumes (wt/vol) of
25 distilled water, centrifuged at 50,000g for 20 min at 4°C, and the resulting supernatant used for the assay. For subcellular fractionation, the method of Mena et al. (1980) was used and the following fractions were collected: P1 (nuclear fraction), P2 (crude
30 synoptosomal fraction), P3 (microsomal fraction), soluble (cytosol fraction), myelin, synaptosomes, and mitochondria. All nonsoluble fractions were sonicated prior to assay.

35 Measurement of 3-HAO activity

For routine assays, 20µl of tissue extract (equivalent

to 5 mg of original tissue wet weight) were incubated in the presence or absence of inhibitor (in 10 μ l) at 37°C for 30 min in a solution containing 0.3 mM Fe (SO₄)₂, 38 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES)/NaOH buffer (pH 6.0), and 5 μ M ([¹⁴C]3HANA in a total volume of 195 μ l. Blank values were obtained under identical conditions using tissue that had been heated for 5 min in a boiling water bath. The incubation was terminated by the addition of 50 μ l 6% HClO₄, the tubes cooled on ice, and the precipitate removed by a 2-min centrifugation in a Beckman microfuge. 220 μ l of supernatant were applied to a Dowex 50W (200-400 mesh) cation-exchange column (0.5 x 2 cm), which was washed with 1 ml of distilled H₂O to collect the [¹⁴C]QUIN produced. 5.5 ml of scintillation fluid were added to the eluate and its radioactivity determined by liquid scintillation spectrometry. Preliminary experiments had indicated that 90-95% of [¹⁴C]QUIN was collected by this procedure, whereas unreacted [¹⁴C]3HANA remained on the column.

Pharmaceutical formulations

The administration in the novel method of treatment of this invention may conveniently be oral, rectal, or parenteral at a dosage level of, for example, about 1 to 3000 mg/kg, preferably about 10 to 1000 mg/kg and especially about 25 to 250 mg/kg and may be administered on a regimen of 1 to 4 hours per day. The dose will depend on the route of administration, a particularly preferred route being by intravenous infusion of an aqueous solution containing a compound according to formula I. It will be appreciated that the severity of the disease, the age of the patient and other factors normally considered by the attending

physician will influence the individual regimen and dosage most appropriate for a particular patient.

5 The pharmaceutical formulations comprising the compound of this invention may conveniently be tablets, pills, capsules, syrups, powders or granules for oral administration; sterile parenteral solutions or suspensions for parenteral administration; or as suppositories for rectal administration.

10

To produce pharmaceutical formulations containing a compound according to the present invention in the form of dosage units for oral application, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatine or polyvinylpyrrolidone, and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated e.g. gum arabic, gelatine, talcum, titanium dioxide, and the like. Alternatively, the tablet can be coated with a polymer known to the person skilled in the art, dissolved in a readily volatile organic solvent or mixture of organic solvents. Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different active substances or different amounts of the active compounds.

30

For the preparation of soft gelatine capsules, the active substance may be admixed with e.g. a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the active substance using either the above-mentioned excipients for tablets e.g. lactose, saccharose, sorbitol, mannitol, starches (e.g. potato starch, corn starch or amylopectin), cellulose

35

derivatives or gelatine. Also liquids or semisolids of the drug can be filled into hard gelatine capsules.

5 Dosage units for rectal application can be solutions or suspensions or can be prepared in the form of suppositories comprising the active substance in admixture with a neutral fatty base, or gelatine rectal capsules comprising the active substance in admixture with vegetable oil or paraffin oil.

10

Liquid preparations for oral application may be in the form of syrups or suspensions, for example solutions containing from 0.2% to about 20% by weight of the active substance herein described, the balance being sugar and mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethylcellulose as a thickening agent or other excipients known to the person skilled in the art.


20

Solutions for parenteral applications by injection can be prepared in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substance, preferably in a concentration of from about 0.5% to about 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules.

30

Claims

1. A compound of the general formula I



wherein

R^1 and R^2 are the same or different and selected from H and alkyl;

X is selected from alkylthio, arylthio, aryloxy, halogen and cyano;

R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1 - C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein alkyl when R^1 , R^2 and/or R^5 represent alkyl, when X represents an alkylthio or when R^3 , R^4 and/or R^5 represent fluoroalkyl is a straight or branched lower alkyl, preferably a C_1 - C_6 alkyl.

3. A compound according to claim 1 wherein X, R^3 and/or R^4 representing a halogen is selected from iodo,

fluoro, chloro and bromo.


4. A compound according to claim 1 wherein aryl when R^5
 5 represents aryl or when X represents an arylthio or
 aryloxy is a phenyl, furyl or thienyl group in which
 the ring is optionally further substituted by lower
 alkyl, lower alkoxy or halogen.

10 5. A compound according to claim 1 being 4,6-dichloro-
 5-methylantranilic acid.

6. A process for the preparation of the compound of
 formula I according to claim 1, by

15 A) in the case where R^1 and $R^2 = H$; X is selected from
 alkylthio, arylthio, aryloxy, halogen and cyano; R^3 ,
 R^4 are the same or different and selected from halogen,
 methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is
 selected from CH_n , NH_m , O, S, SO_2 and CO wherein n = 1
 20 or 2; m = 0 or 1 and R^5 is selected from alkyl, aryl
 and fluoroalkyl; or R^3 and R^4 together form a saturated
 or unsaturated ring system Y-V-Z wherein Y and Z,
 independently of each other, are as defined for Z above
 and V is selected from C_1-C_3 alkylene or alkenylene,
 25 -N=, -N=N- and -N- R_7 wherein $R_7 = H$ or alkyl

reducing a compound of formula II




35 wherein X, R^3 and R^4 are as defined in A) above,

B) in the case where R^1 and R^2 are the same or

different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, -N=, -N=N- and $-N-R_7$ wherein $R_7 = H$ or alkyl

deprotecting a compound of formula III

15



20

wherein R^1 , R^2 , X, R^3 and R^4 are as defined in B) above and PG is a protecting group such as alkyl, benzyl (Bn), 2-(trimethylsilyl)ethoxymethyl (SEM), methoxymethyl (MOM) or 2-methoxyethoxymethyl (MEM),


25

C) in the case where R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, -N=, -N=N- and $-N-R_7$ wherein $R_7 = H$ or alkyl

35

deesterifying a compound of formula IV

5



IV


wherein R^1 , R^2 , X , R^3 and R^4 are as defined in C) above and R^6 is selected from alkyl, Bn, SEM, MEM, MOM and 2,2,2-trichloroethyl,

D) in the case where R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and Z-R^5 wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from $\text{C}_1\text{-C}_3$ alkylene or alkenylene, $-\text{N}=\text{}$, $-\text{N}=\text{N}-$ and $-\text{N}-\text{R}_7$ wherein $\text{R}_7 = \text{H}$ or alkyl

25

deesterifying and deprotecting a compound of formula V

30




V

wherein R^1 , R^2 , X , R^3 and R^4 are as defined in D) above and R^6 and PG are selected from alkyl, Bn, SEM, MEM and MOM,

35

E) in the case where R^1 = alkyl, R^2 = H or alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein R_7 = H or alkyl


alkylating a compound of formula VI



wherein X, R^3 and R^4 are as defined in E) above.

F) in the case where R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, halogen and cyano; R^3 = chloro, bromo or iodo; R^4 = alkoxy, alkyl, alkylthio, cyano, fluoroalkyl, halogen, RSO_2 or RCO wherein $R = C_1-C_5$ alkyl

halogenating a compound of formula VII



wherein R^1 , R^2 , X and R^4 are as defined in F)


above,

5

G) in the case where R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, halogen and cyano; R^3 = alkoxy, alkyl, alkythio, cyano, fluoroalkyl, halogen, RSO_2 or RCO
 10 wherein R = C_1 - C_5 alkyl and R^4 = chloro, bromo or iodo

halogenation a compound of formula VIII

15



20

wherein R^1 , R^2 , X and R^3 are as defined in G)


above,

or

25

H) in the case where R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from chloro, bromo and iodo; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from
 30 CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected
 35 from C_1 - C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl

halogenating a compound of formula IX



10 wherein R¹, R², R³ and R⁴ are as defined in H) above.

15 7. A pharmaceutical formulation containing a compound according to claim 1 as active ingredient and a pharmaceutically acceptable carrier.


8. A compound according to claim 1 for use in therapy.

9. A compound as defined in claim 8 for use as an agent for prevention or treatment of neurodegeneration.

20 10. The use of a compound according to claim 1 for the manufacture of a medicament for the prevention or treatment of neurodegeneration.


25 11. A method for the prevention or treatment of neurodegeneration by administering to a host in need of such a treatment a sufficient amount of a compound according to claim 1.

30 12. A compound of the general formula II




wherein X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl.

13. A compound of the general formula III




wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2 ; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl and PG is a protecting group, such as alkyl, benzyl (Bn), 2-(trimethylsilyl)ethoxymethyl (SEM), methoxymethyl (MOM) or 2-methoxyethoxymethyl (MEM).

14. A compound of the general formula IV



10 wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1-C_3 alkylene or alkenylene, 15
20 $-N=$, $-N=N-$ and $-N-R_7$ wherein $R_7 = H$ or alkyl and R^6 is selected from alkyl, Bn, SEM, MEM, MOM and 2,2,2-trichloroethyl.


15. A compound of the general formula V



35 wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$


or 2; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1 - C_3 alkylene or alkenylene, -N=, -N=N- and -N- R_7 wherein $R_7 = H$ or alkyl; R^6 and PG are selected from alkyl, Bn, SEM, MEM and MOM.

16. A compound of the general formula VI



wherein X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and Z- R^5 wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein $n = 1$ or 2; $m = 0$ or 1 and R^5 is selected from alkyl, aryl and fluoroalkyl; or R^3 and R^4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1 - C_3 alkylene or alkenylene, -N=, -N=N- and -N- R_7 wherein $R_7 = H$ or alkyl.

17. A compound of the general formula VII




wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, halogen and cyano; R^4 is selected from RSO_2 and RCO wherein R = C_1 - C_5 alkyl.

5

18. A compound of the general formula VIII

10




15

wherein R^1 and R^2 are the same or different and selected from H and alkyl; X is selected from alkylthio, halogen and cyano; R^3 is selected from RSO_2 and RCO wherein R = C_1 - C_5 alkyl.

20

19. A compound of the general formula IX

25



30

wherein R^1 and R^2 are the same or different and selected from H and alkyl; R^3 , R^4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and $Z-R^5$ wherein Z is selected from CH_n , NH_m , O, S, SO_2 and CO wherein n = 1 or 2; m = 0 or 1 and R^5 is selected from alkyl and fluoroalkyl; or R^3 and R^4 together form a saturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C_1 - C_3 alkylene or alkenylene, -N=, -N=N- and $-N-R_7$ wherein R_7 = H or alkyl.

35

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00152

A. CLASSIFICATION OF SUBJECT MATTER

IPC5: C07C 229/64, C07C 323/63, C07C 255/59, A61K 31/195, C07C 205/59
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: A61K, C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

REGISTRY

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PREPARATIVE BIOCHEMISTRY, Volume 19, No 2, 1989, William P. Todd et al, "PREPARATION OF 4-HALO-3-HYDROXYANTHRANILATES AND DEMONSTRATION OF THEIR INHIBITION OF 3-HYDROXYANTHRANILATE OXYGENASE ACTIVITY IN RAT AND HUMAN BRAIN TISSUE" page 155 - page 165	1-6,12-19
X	--	7-10
A	J. CHEM. RESEARCH (M), 1978, Wolfgang Prinz, et al: "A Novel Synthetic Route to Oximinoacet-2-anisidides and their Conversion into 3-Hydroxyanthranilic Acids via 7-Methoxyisatins", page 1347 - page 1370 -----	1-10,12-19

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

2 June 1994

08 -06- 1994

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer
Elisabeth Carlborg
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00152

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 11
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☒ Claims Nos.: 1, 4, 7, 8, 10, 12-16 and 19
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The definition of R³ and R⁴ as together forming a heterocyclic ring system is too broad to permit a meaningful search. Therefore, the search on the mentioned claims has been incomplete.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.